Listened in. Rick is certainly good at delivering any type of news.
Didn't observe any hesitation, desperation or missteps in what was being communicated.
It was mentioned EBITDA for H1 and H2 will still be positive.
The Bell Potter report from July put forward some projected numbers.
I would suggest the FY25 column will be curbed and revert closer to FY24 numbers.
This puts pressure on future years to reach the aspired $250M revenue.
Questions from Bell Potter, Cannacord, Peloton, DMX.
Many questions seeking clarification if revenue is lost or deferred. Responses appeared to indicate both was true. Whilst diversification of customers and products is good, it de-risks losing a large program, it would need to deliver complimentary spend from those additional, smaller programs but it also comes with additional overhead/management/development.
Touched on the US market with names who are competitors or overlap capabilities with MDR, mentioned names who might be of interest in bolting on and names of private equity who make investments / acquisitions.
https://www.fiercehealthcare.com/health-tech/pe-firm-tpg-buys-majority-stake-health-information-network-surescripts
Add to My Watchlist
What is My Watchlist?
